# A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor

> **NCT01458236** · PHASE3 · WITHDRAWN · sponsor: **Lung Biotechnology PBC**

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Beraprost Sodium 314d Modified Release Tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01458236
- **Lead sponsor:** Lung Biotechnology PBC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-11
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01458236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01458236, "A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01458236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*